Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia.
Amino Acid Transport Systems, Neutral
/ genetics
Exome
Eye Proteins
/ genetics
Genomics
Humans
Leukemia, Large Granular Lymphocytic
/ genetics
Mutation
Nerve Tissue Proteins
/ genetics
RNA Helicases
/ genetics
Receptors, Antigen, T-Cell, alpha-beta
/ genetics
Receptors, Antigen, T-Cell, gamma-delta
/ metabolism
STAT3 Transcription Factor
/ genetics
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
19 05 2022
19 05 2022
Historique:
received:
02
07
2021
accepted:
18
12
2021
pubmed:
12
1
2022
medline:
24
5
2022
entrez:
11
1
2022
Statut:
ppublish
Résumé
Large granular lymphocyte (LGL) leukemia comprises a group of rare lymphoproliferative disorders whose molecular landscape is incompletely defined. We leveraged paired whole-exome and transcriptome sequencing in the largest LGL leukemia cohort to date, which included 105 patients (93 T-cell receptor αβ [TCRαβ] T-LGL and 12 TCRγδ T-LGL). Seventy-six mutations were observed in 3 or more patients in the cohort, and out of those, STAT3, KMT2D, PIK3R1, TTN, EYS, and SULF1 mutations were shared between both subtypes. We identified ARHGAP25, ABCC9, PCDHA11, SULF1, SLC6A15, DDX59, DNMT3A, FAS, KDM6A, KMT2D, PIK3R1, STAT3, STAT5B, TET2, and TNFAIP3 as recurrently mutated putative drivers using an unbiased driver analysis approach leveraging our whole-exome cohort. Hotspot mutations in STAT3, PIK3R1, and FAS were detected, whereas truncating mutations in epigenetic modifying enzymes such as KMT2D and TET2 were observed. Moreover, STAT3 mutations co-occurred with mutations in chromatin and epigenetic modifying genes, especially KMT2D and SETD1B (P < .01 and P < .05, respectively). STAT3 was mutated in 50.5% of the patients. Most common Y640F STAT3 mutation was associated with lower absolute neutrophil count values, and N647I mutation was associated with lower hemoglobin values. Somatic activating mutations (Q160P, D170Y, L287F) in the STAT3 coiled-coil domain were characterized. STAT3-mutant patients exhibited increased mutational burden and enrichment of a mutational signature associated with increased spontaneous deamination of 5-methylcytosine. Finally, gene expression analysis revealed enrichment of interferon-γ signaling and decreased phosphatidylinositol 3-kinase-Akt signaling for STAT3-mutant patients. These findings highlight the clinical and molecular heterogeneity of this rare disorder.
Identifiants
pubmed: 35015834
pii: S0006-4971(22)00042-8
doi: 10.1182/blood.2021013164
pmc: PMC9121841
doi:
Substances chimiques
Amino Acid Transport Systems, Neutral
0
EYS protein, human
0
Eye Proteins
0
Nerve Tissue Proteins
0
Receptors, Antigen, T-Cell, alpha-beta
0
Receptors, Antigen, T-Cell, gamma-delta
0
SLC6A15 protein, human
0
STAT3 Transcription Factor
0
DDX59 protein, human
EC 2.7.7.-.
RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3058-3072Subventions
Organisme : NCI NIH HHS
ID : P30 CA044579
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178393
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009109
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007267
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 by The American Society of Hematology.
Références
Blood. 2012 Oct 11;120(15):3048-57
pubmed: 22859607
Oncotarget. 2018 May 25;9(40):25826-25832
pubmed: 29899824
Blood. 2011 Mar 10;117(10):2764-74
pubmed: 21190991
Cancer Cell. 2009 Dec 8;16(6):463-74
pubmed: 19962665
Blood. 2015 Jan 1;125(1):13-21
pubmed: 25320243
Blood. 2010 Jan 7;115(1):51-60
pubmed: 19880494
Am J Hematol. 2017 Jan;92(1):E6-E8
pubmed: 27761930
Front Immunol. 2018 Feb 27;9:369
pubmed: 29535736
J Exp Med. 2014 Dec 15;211(13):2537-47
pubmed: 25488983
Blood. 1998 Dec 15;92(12):4771-7
pubmed: 9845544
Blood. 2013 May 30;121(22):4541-50
pubmed: 23596048
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
J Clin Invest. 1992 Aug;90(2):334-41
pubmed: 1386609
Blood. 2009 Mar 19;113(12):2746-54
pubmed: 19139084
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Int J Hematol. 2019 May;109(5):563-571
pubmed: 30859397
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Nucleic Acids Res. 2014 Jan;42(Database issue):D142-7
pubmed: 24194598
Cell Cycle. 2014;13(21):3331-5
pubmed: 25485578
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Leukemia. 2020 Apr;34(4):1116-1124
pubmed: 31740810
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980
pubmed: 28356514
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nat Med. 2015 Oct;21(10):1190-8
pubmed: 26366712
Leukemia. 2021 Dec;35(12):3430-3443
pubmed: 34075200
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
J Clin Invest. 2014 Sep;124(9):3923-8
pubmed: 25133428
Clin Immunol. 2017 Mar;176:77-86
pubmed: 28104464
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5569-74
pubmed: 17376864
Nat Genet. 2009 May;41(5):521-3
pubmed: 19330029
Cancer Discov. 2012 Jul;2(7):591-7
pubmed: 22705984
Leukemia. 2013 Jul;27(7):1598-600
pubmed: 23207521
Mol Biol Cell. 2016 Sep 1;27(17):2653-61
pubmed: 27413008
Int J Cancer. 2016 Jan 1;138(1):121-4
pubmed: 26199174
Am J Clin Pathol. 2011 Aug;136(2):289-99
pubmed: 21757603
Blood. 2017 Mar 2;129(9):1082-1094
pubmed: 28115367
Ann Intern Med. 1985 Feb;102(2):169-75
pubmed: 3966754
Leukemia. 2006 Mar;20(3):505-13
pubmed: 16437145
Oncotarget. 2017 Jun 27;8(37):61876-61889
pubmed: 28977911
Curr Hematol Malig Rep. 2020 Apr;15(2):103-112
pubmed: 32062772
Br J Haematol. 1997 Apr;97(1):123-6
pubmed: 9136951
Front Oncol. 2020 Feb 18;10:152
pubmed: 32133291
Blood. 2021 Aug 26;138(8):662-673
pubmed: 33786584
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902
pubmed: 9391124
Leukemia. 2013 Nov;27(11):2244-7
pubmed: 23563237
Blood. 2006 Jun 15;107(12):4834-40
pubmed: 16484592
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Leukemia. 2017 May;31(5):1243-1246
pubmed: 28167832
Onco Targets Ther. 2019 Aug 19;12:6699-6710
pubmed: 31692494
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Cancer Med. 2020 Sep;9(18):6533-6549
pubmed: 32710512
Best Pract Res Clin Haematol. 2019 Sep;32(3):196-206
pubmed: 31585620
Blood. 2021 Jun 10;137(23):3237-3250
pubmed: 33512451
Nat Rev Cancer. 2020 Oct;20(10):555-572
pubmed: 32778778
Blood. 2016 Nov 17;128(20):2465-2468
pubmed: 27697773
Blood. 2010 Jun 24;115(25):5164-9
pubmed: 20360470
Blood Cancer J. 2020 Apr 22;10(4):42
pubmed: 32321919
Blood. 2020 Jan 30;135(5):360-370
pubmed: 31774495
Sci Transl Med. 2017 Feb 22;9(378):
pubmed: 28228601
J Clin Invest. 2001 Feb;107(3):351-62
pubmed: 11160159
Bioinformatics. 2017 Jan 1;33(1):8-16
pubmed: 27591080
Clin Cancer Res. 2020 Apr 15;26(8):2065-2079
pubmed: 32047002
Front Biosci (Landmark Ed). 2009 Jan 01;14(10):3771-81
pubmed: 19273309
N Engl J Med. 2004 Sep 30;351(14):1409-18
pubmed: 15459302
Cancer Cell. 2020 Apr 13;37(4):599-617.e7
pubmed: 32243837